Apollo's €3 Billion Bet Meets a German Drug Pricing Shock as Bayer's Rally Hits a Technical Ceiling
Published on 07/12/2026 at 04:43 | Redaktion boerse-global.de
Bayer shares ended the week at €50.18, shedding 1.03% on Friday, as two opposing forces collided. Just days after the German chemicals and pharmaceuticals group secured a €3 billion minority investment from Apollo Global Management, the Bundestag passed legislation that sharply increases the cost of selling patented drugs in Germany. The stock, still hovering near its 52-week high of €53.86, must now absorb both a bullish capital infusion and a bearish regulatory blow while technicians warn that the rally has already run too far, too fast.
The Apollo transaction, expected to close in the third quarter of 2026 pending regulatory approvals, sees the US investor take a minority stake in Bayer’s LARC (long-acting reversible contraception) business, which houses brands such as Mirena and Kyleena. Bayer retains majority control and operational oversight. The LARC unit generated €1.37 billion in revenue in 2025. The deal provides fresh equity without the dilution of a rights offering, easing fears that Bayer would need to tap shareholders to fund settlements in the ongoing US glyphosate litigation. For bulls, the structure preserves the company’s most profitable core assets while gaining financial flexibility.
Yet on the same Friday, Berlin dealt a direct blow to Bayer’s pharmaceutical margins. The Bundestag voted 318-284 with four abstentions to pass the GKV-Beitragssatzstabilisierungsgesetz, which raises the statutory manufacturer discount on patented drugs from a dynamic 7% to a fixed 15.5% — an increase of 8.5 percentage points. The discount on vaccines also rises to 9%. The Bundesrat approved the bill in the afternoon, declining to call a mediation committee. The pharmaceutical industry lobby, led by Verband der forschenden Pharma-Unternehmen president Han Steutel, immediately condemned the move, warning it would undermine investment conditions for research and production in Germany and could delay or prevent the launch of new medicines in the country. The government has offered transition relief: exceptions from the additional discount until January 1, 2027, and an interministerial expert group that must deliver legally sound implementation proposals by the end of September 2026. Still, the margin pressure on Bayer’s German pharma business is now a concrete headwind, with the first operational effects expected to surface in quarterly results.
Should investors sell immediately? Or is it worth buying Bayer?
Technically, the stock is stretched. Over the past 30 days, the share price has surged 42.60%, pushing the 14-day relative strength index to 70.4 — firmly in overbought territory. The distance to the 200-day moving average of €37.68 stands at roughly 33%, and annualized volatility of nearly 62% underscores the stock’s sensitivity to news. Friday’s modest decline, even as the Apollo news was becoming known, may already signal profit-taking after the breakneck run that has lifted the stock 32% since the start of the year and nearly 81% over twelve months.
The competing narratives set the stage for a tug-of-war in the coming weeks. On the bullish side, the Apollo deal reduces the likelihood of a dilutive capital increase, leaves Bayer in control of its key growth franchise, and provides a stronger balance sheet to negotiate US glyphosate settlements. The stock remains above its 50-day average of €40.16, and a test of the 52-week high looks plausible if confidence in the legal resolution gains momentum. The bear case, however, points to the stretched valuation, the “sell the news” risk after the rally, and the interpretation of the Apollo transaction as a disposal of crown jewels to cover legacy liabilities. The new German drug pricing law adds a direct hit to earnings that has yet to be fully priced in.
Key support now sits at the psychologically important €50 level. If that holds on a closing basis, a healthy consolidation of the year-to-date gains may follow. A decisive break below €50 could open the door to a slide back toward the 50-day moving average at €40.16. The next major catalysts are the antitrust clearance for the Apollo deal — due in the third quarter of 2026 — and the final approval hearing for the glyphosate settlement, which has been postponed to August 19. In the near term, analyst rating changes on the back of the capital structure shift will likely determine whether the overbought rally pauses or reverses.
Ad
Bayer Stock: New Analysis - 12 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
